TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype

Blood. 2023 Mar 2;141(9):1087-1091. doi: 10.1182/blood.2022018236.
No abstract available

MeSH terms

  • Humans
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Myeloid, Acute* / therapy
  • Mutation
  • Myeloproliferative Disorders* / genetics
  • Tumor Suppressor Protein p53 / genetics

Substances

  • TP53 protein, human
  • Tumor Suppressor Protein p53